BioLineRx

The firm was established in 2003 as a joint venture of Teva, Hadasit Bio-Holdings, the Jerusalem Development Authority, Yehuda Zisapel, and other investors.{{cite news|last=Grayeff|first=Yigal|date=13 January 2005|title=BioLineRx signs 3 deals to develop drugs|work=The Jerusalem Post|url=http://www.ivc-online.com/ivcWeeklyItem.asp?articleID=2656|url-status=dead|access-date=28 November 2011|archive-url=https://web.archive.org/web/20100203030129/http://www.ivc-online.com/ivcWeeklyItem.asp?articleID=2656|archive-date=3 February 2010|via=IVC Research Center}} It executed an initial public offering on the Tel Aviv Stock Exchange in February 2007, raising 211 million NIS ($50 million) – the TASE's largest biotech IPO until that time.{{cite news|last=Cohen|first=Omri|date=7 February 2007|title=Biotech comes of age: Bioline floats at half-billion shekel market cap|newspaper=TheMarker|url=http://www.haaretz.com/news/biotech-comes-of-age-bioline-floats-at-half-billion-shekel-market-cap-1.212200|access-date=28 November 2011|quote=Bioline Therapeutics today pulled off its initial public offering in Tel Aviv, raising NIS 211 million at a company valuation of NIS 494 million, making this the biggest flotation by a biotechnology company in local history.}}{{cite news|last=Rheinheimer|first=Laura|date=8 February 2007|title=BioLineRx raises $50m. in TASE's largest biomedical IPO|newspaper=The Jerusalem Post|url=http://www.jpost.com/Business/Commentary/Article.aspx?id=50790|access-date=28 November 2011|quote=BioLineRx Ltd. on Wednesday priced the largest ever initial public offering of a biomedical company on the Tel Aviv Stock Exchange, raising a total of NIS 211 million, or $50m.}} In July 2011 BioLine's ADRs began trading on the NASDAQ Capital Market.{{cite news|date=25 July 2011|title=BioLineRx ADRs Begin Trading on NASDAQ|url=https://www.businesswire.com/news/home/20110725005621/en/BioLineRx-ADRs-Trading-NASDAQ|access-date=27 April 2019}}{{cite news|last=Cohen|first=Tova|date=24 July 2011|title=BioLineRX ADRs to begin trading on Nasdaq Monday|work=Reuters|editor-last=Magnowski|editor-first=Daniel|url=https://www.reuters.com/article/biolinerx-adr-idUSLDE76N01720110724|access-date=30 June 2017|archive-date=24 September 2015|archive-url=https://web.archive.org/web/20150924154320/http://www.reuters.com/article/2011/07/24/biolinerx-adr-idUSLDE76N01720110724|url-status=live}} In January 2012, the firm announced a deal with Genoscience, a French pharmaceutical company to jointly develop and market the BL-8020 compound, as a treatment for Hepatitis C.{{cite news|last=Wang|first=Lu|date=24 January 2012|title=Achillion, BioLineRx, J&J Snack, Rubicon: U.S. Equity Movers|agency=Bloomberg News|url=http://www.businessweek.com/news/2012-01-24/achillion-biolinerx-j-j-snack-rubicon-u-s-equity-movers.html|url-status=dead|archive-url=https://web.archive.org/web/20120124181829/http://www.businessweek.com/news/2012-01-24/achillion-biolinerx-j-j-snack-rubicon-u-s-equity-movers.html|archive-date=24 January 2012}} At the end of 2014, Novartis acquired a 12.8% stake in the company as a strategic move to gain access to Israeli-sourced drug candidates.{{cite news|date=16 December 2014|title=Novartis Makes $10M Investment in BioLineRx|volume=35|page=9|work=Genetic Engineering & Biotechnology News|issue=2|department=Industry Watch|url=http://www.genengnews.com/gen-news-highlights/novartis-makes-10m-investment-in-biolinerx/81250706/}}

Morris Laster, (M.D.) an alumnus of. Downstate Medical Center, was CEO of BioLineRx until 2009. He was replaced by Kinneret Savitsky, alumnus of Tel Aviv University early in 2010.{{cite web|title=Kinneret Livnat Savitsky Ph.D.: Executive Profile & Biography|url=https://www.bloomberg.com/research/stocks/people/person.asp?personId=8011457|access-date=21 February 2015|publisher=Bloomberg Business}} Savitsky was replaced as CEO by BioLine COO Philip Serlin on October 10, 2016.

File:BioLineRx.png

BioLineRx is a drug development company When promising compounds are discovered, the firm leads them through preclinical trials and engages other companies to further develop them into commercializable drugs.{{cite news

|last=Brinn |first=David |title=BioLineRx—Israel's biotech supermarket |url=http://www.israel21c.org/health/biolinerx-israel-s-biotech-supermarket |access-date=28 November 2011 |work=ISRAEL21c |date=3 June 2007 |url-status=dead |archive-date=5 April 2012 |archive-url=https://web.archive.org/web/20120405235441/http://www.israel21c.org/health/biolinerx-israel-s-biotech-supermarket }} The company entered into its first major commercialization agreement in 2009 when it partnered with Ikaria Holdings Inc. to develop its BL-1040 compound.{{cite news|last=Habib-Valdhorn|first=Shiri|title=BiolineRX earns $10m milestone payment|url=http://www.globes.co.il/serveen/globes/docview.asp?did=1000555803&fid=1725|archive-url=https://archive.today/20120803014242/http://www.globes.co.il/serveen/globes/docview.asp?did=1000555803&fid=1725|url-status=dead|archive-date=3 August 2012|access-date=28 November 2011|newspaper=Globes|date=28 April 2010}} In 2010, BioLine entered into a commercialization agreement with Cypress Bioscience Inc. for development of its BL-1020 compound. The agreement with Cypress was canceled in 2011 when the company was taken over by Ramius LLC.{{cite news|last=Weinreb|first=Gali|title=BiolineRX and Cypress cancel schizophrenia drug agreement|url=http://www.globes.co.il/serveen/globes/docview.asp?did=1000644520&fid=1725|access-date=28 November 2011|newspaper=Globes|date=11 May 2011|url-status=dead|archive-url=https://web.archive.org/web/20110615064401/http://www.globes.co.il/serveen/globes/docview.asp?did=1000644520&fid=1725|archive-date=15 June 2011}}

Below is a partial list of drug compounds in various stages of development by BioLineRx. Unless indicated otherwise, they have not obtained regulatory approval in relation to the diseases cited.

• BL-1010 – orally available neuropathic pain{{cite news|title=BioLineRx In-Licenses Novel Compound for Treatment of Neuropathic Pain|url=http://www.biolinerx.com/default.asp?pageid=16&itemid=284|url-status=dead|archive-url=https://web.archive.org/web/20150926232047/http://www.biolinerx.com/default.asp?pageid=16&itemid=284|archive-date=2015-09-26}}
• BL-1020 – orally available GABA-enhanced antipsychotic for treatment of schizophrenia{{cite news|title=Israeli co to hold clinical trial for treatment of Schizophrenia in India|url=http://www.thehindubusinessline.com/industry-and-economy/economy/article2655585.ece?homepage=true|access-date=28 November 2011|newspaper=The Hindu Business Line|date=24 November 2011|location=Jerusalem}}
• BL-1021 – orally available small molecule for treatment of neuropathic pain{{cite press release

|title=BioLineRx Announces Positive Preliminary Results from Phase I Clinical Trial of BL-1021 for Neuropathic Pain |url=http://www.businesswire.com/news/home/20110913006058/en/BioLineRx-Announces-Positive-Preliminary-Results-Phase-Clinical |access-date=28 November 2011 |via=Business Wire |date=13 September 2011 |location=Jerusalem |author=BioLineRx }}

• BL-1040 – liquid polymer injected into patients with acute myocardial infarction, invented by Smadar Cohen of Ben-Gurion University{{cite news|title=Bioline looks to heart attack treatment clinical trial|url=http://www.globes.co.il/serveen/globes/docview.asp?did=1000626251&fid=1725|archive-url=https://archive.today/20120803143138/http://www.globes.co.il/serveen/globes/docview.asp?did=1000626251&fid=1725|url-status=dead|archive-date=3 August 2012|access-date=28 November 2011|newspaper=Globes|date=27 February 2011}}{{cite news|title=US company buys exclusive license for Israeli heart attack drug for $285 million|url=http://www.israel21c.org/briefs/us-company-buys-exclusive-license-for-israeli-heart-attack-drug-for-285-million|access-date=28 November 2011|newspaper=Israel21c|date=8 July 2009}}
• BL-1230 - a selective cannabinoid receptor type 2 (CB2R) agonist for Dry Eye Syndrome (DES) {{cite web |url=http://www.biolinerx.com/default.asp?pageid=96&itemid=47 |title=Other |website=www.biolinerx.com |url-status=dead |archive-url=https://web.archive.org/web/20161202235534/http://www.biolinerx.com/default.asp?pageid=96&itemid=47 |archive-date=2016-12-02}}
• BL-5010 – cream treatment for seborrheic keratosis skin lesions{{cite news|last=Wrobel|first=Sharon|title=Bioline RX Gets European Device Confirmation for Bl-5010 Drug|url=https://www.bloomberg.com/news/2011-09-15/bioline-rx-gets-european-device-confirmation-for-bl-5010-drug.html|access-date=28 November 2011|newspaper=Bloomberg|date=15 September 2011}}
• BL-7040 – orally available anti-inflammatory drug invented by Hermona Soreq of the Hebrew University of Jerusalem{{cite web|title=BioLineRx has acquired the rights to compound BL-7040 from Yissum and Prof. Soreq|url=http://elsc.huji.ac.il/content/biolinerx-has-acquired-rights-compound-bl-7040-yissum-and-prof-soreq|work=The Hebrew University of Jerusalem|publisher=The Edmond and Lily Safra Center for Brain Sciences|access-date=28 November 2011|date=27 June 2011|archive-url=https://web.archive.org/web/20110712214142/http://elsc.huji.ac.il/content/biolinerx-has-acquired-rights-compound-bl-7040-yissum-and-prof-soreq|archive-date=12 July 2011|url-status=dead}}
• BL-8020 – orally administered treatment for Hepatitis C, developed by Philippe Halfon, co-founder and President of Genoscience.
• BL-8030 – second-generation NS3 protease inhibitor for oral treatment of Hepatitis C, invented by Philippe Halfon{{cite news|title=BioLineRx signs pact with Genoscience & RFS Pharma to develop and commercialize BL-8030 to treat hepatitis C|url=http://pharmabiz.com/NewsDetails.aspx?aid=67413&sid=2|access-date=8 February 2012|newspaper=Pharmabiz.com|date=8 February 2012|location=Jerusalem, Israel|url-status=dead|archive-url=https://web.archive.org/web/20150221003613/http://pharmabiz.com/NewsDetails.aspx?aid=67413&sid=2|archive-date=21 February 2015}}

• TA BlueTech Index
• List of Israeli companies quoted on the Nasdaq

{{reflist|30em}}

• [http://www.biojerusalem.org.il/ BioJerusalem]
• [https://web.archive.org/web/20111003051153/http://www.jda.gov.il/Front/ShowCategory.aspx?CatId=112 Jerusalem Development Authority]
• [https://web.archive.org/web/20111120031902/http://www.moit.gov.il/CmsTamat/Rsrc/MadaanEnglish/MadaanEnglish.html Office of the Chief Scientist of Israel]

{{Israel NASDAQ}}

Category:Companies listed on the Tel Aviv Stock Exchange

Category:Biotechnology companies established in 2003

Category:Biotechnology companies of Israel

Category:Companies listed on the Nasdaq

Category:Drug discovery companies

Category:2003 establishments in Israel